2020-03-12 08:00 Regulatory Interim
Significant events during the third quarter Significant events after the end of the period Audiocast When: 12 March 2020 at 10.00 CET Where: https://tv.streamfabriken.com/biovica-international-q3-2019-2020 or SE: +46850558352 / DK: +4578150110...
2019-12-05 08:00 Regulatory Interim
Period: May-October 2019/2020 Significant events during the second quarter Significant events after the end of the period Audiocast When: 6 December 2019 at 10.00 CET Where: https://tv.streamfabriken.com/biovica-international-q2-2019...
2019-08-29 08:00 Regulatory Interim
Significant events during the first quarter Significant events after the end of the period CEO’s comments Commercialization of DiviTum® for breast cancer During the first quarter of the new financial year, we achieved several important milestones...
2019-06-14 08:00 Regulatory Interim
Significant events during the fourth quarter Significant events after the end of the period CEO's comments Commercialization of DiviTum® for breast cancer During the fourth quarter, we achieved several important milestones for launching DiviTum®...
2019-03-21 08:00 Regulatory Interim
CEO’s comments Continued focus on commercialization of DiviTum® The focus of Biovica’s business plan is commercialization of DiviTum®, which will provide cancer patients with more personalized treatments leading to better outcomes...

>4,500

Numbers of patients in studies

28

Publications

22

Pharma Projects

Are you a US resident?

Only US residents will be able to qualify for this program

No